RSV vaccine in people with immune suppression: how antibodies form and work
Official title: The Impact of Systemic Immunosuppression on RSV Antibody Generation and Effector Functions After Vaccination
Funded at Johns Hopkins University · NIH-11384417 · Data updated 2026-11-12
This grant studies how vaccines for RSV work in people with weakened immune systems and aims to improve how vaccines protect them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | August 1, 2025 |
| Project end | July 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $777,478 |
| NIH project number | 5R01AI190195-02 |
| Project ID | NIH-11384417 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with autoimmune diseases or on immunosuppressive therapy who may receive RSV vaccination.
✕Less likely to help
People without immune suppression or those not receiving RSV vaccines are not the target for this research.
What this research studies
If you have an autoimmune condition or are taking immune-suppressing medicines, your response to RSV vaccines might be weaker. The project will look at how antibodies develop after vaccination and how well they protect against RSV in these individuals. Researchers will compare responses to different vaccine types, including with and without adjuvants, and examine how specific medicines affect antibody quality and function. The goal is to inform better vaccine choices and medical management so high-risk patients stay safer during RSV seasons.
Why it matters
Potential benefit: It could lead to more effective vaccination strategies for people with immune suppression, reducing RSV hospitalizations.
How similar studies have gone: Preliminary data suggest variable antibody responses in immunosuppressed individuals, with room for improved vaccine strategies.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Karaba, Andrew Hoover — Johns Hopkins University
- Study coordinator: Karaba, Andrew Hoover
Related research
Other NIH-funded projects on the same topics.
-
Next-generation vaccine ideas to prevent C. difficile illness
A new C. difficile vaccine approach is being tested to protect people from serious stomach infections.
-
A New Vaccine for C. difficile Infection
This project aims to create a better vaccine to protect people from serious C. difficile infections.
-
Improving vaccines to prevent C. difficile infections.
This study is working on a new vaccine to help protect people from Clostridioides difficile infections, which can cause serious stomach problems, by using a safe version of a toxin to boost the immune system, and it will also look at how this bacteria might make vaccines less effective.
-
Vascular signals from brain blood vessels influence immune-suppressing cells in glioblastoma
This grant explores how blood vessel cells in glioblastoma shape immune cells to help the tumor grow, with the aim of making immunotherapies work better for patients.
-
Protective dengue vaccines that steer T and B cell responses
A vaccine study aims to guide the body’s T and B cells to fight all four dengue virus types safely and effectively.
-
Vascularized niche with local immune protection to transplant insulin-producing cells for Type 1 diabetes
A new approach aims to transplant insulin-producing cells inside a vascularized pocket with local drug delivery to keep them alive and functioning without full-body immune suppression.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.